Amplia CEO & MD, Dr Chris Burns, visited the Calvary Mater Hospital in Newcastle last week, where patient enrolment is now open as part of the Phase 2a portion of Amplia’s ACCENT clinical trial of narmafotinib in pancreatic cancer patients.
Thank you to journalist @Risa Utama of @NBN News for making the time to visit the hospital to learn more about the ACCENT trial, and how Amplia is working towards improving treatment outcomes for pancreatic cancer patients, like Lorraine Gibbs.
Lorraine was so generous with her time and is a tireless advocate for clinical research that can assist people facing a pancreatic cancer diagnosis.
Click here to watch the segment.
